Finding peptide half-life data usually means digging through a dozen Reddit threads and hoping someone cited an actual study. This is the consolidated reference — 35+ research peptides with half-lives, routes, and sources in one table.
A quick note on data quality: some peptides have published pharmacokinetic studies with precise half-life measurements in humans. Others have only animal data or community-estimated values. The table marks which is which so you know what you’re working with.
What half-life means (and what it doesn’t)
Elimination half-life is the time it takes for plasma concentration to drop by 50%. After about 4-5 half-lives, the compound is effectively cleared.
Half-life is NOT the same as duration of action. BPC-157 has a very short half-life (~minutes IV), but its downstream effects on gene expression and signaling pathways persist much longer. Semaglutide’s 7-day half-life aligns well with its duration of action because it works through sustained receptor occupancy. Different mechanisms, different relationships.
Factors that affect half-life: molecular weight (larger = generally longer), modifications (fatty acid acylation, PEGylation, DAC conjugation), route of administration (IV is fastest clearance, subQ creates a depot), and protein binding (albumin binding dramatically extends half-life).
Complete peptide half-life reference table
| Peptide | Half-Life | Route | Category | Data Source |
|---|---|---|---|---|
| GLP-1 Receptor Agonists | ||||
| Semaglutide | ~168 hours (7 days) | SubQ / Oral | GLP-1 agonist | Published PK (FDA label) |
| Tirzepatide | ~120 hours (5 days) | SubQ | GIP/GLP-1 dual agonist | Published PK (Coskun et al., 2018, PMID: 30473097) |
| Retatrutide | ~144 hours (6 days) | SubQ | GIP/GLP-1/GCGR triple agonist | Published PK (Urva et al., 2022, PMID: 36354040) |
| Exenatide | ~2.4 hours | SubQ | GLP-1 agonist | Published PK (FDA label) |
| Liraglutide | ~13 hours | SubQ | GLP-1 agonist | Published PK (FDA label) |
| Cagrilintide | ~7 days | SubQ | Amylin analog | Published PK (Enebo et al., 2021, PMID: 33894838) |
| Growth Hormone Secretagogues | ||||
| CJC-1295 DAC | ~8 days | SubQ | GHRH analog (DAC-conjugated) | Published PK (Teichman et al., 2006, PMID: 16352683) |
| CJC-1295 (no DAC) | ~30 minutes | SubQ | GHRH analog | Published PK (Teichman et al., 2006) |
| Ipamorelin | ~2 hours | SubQ / IV | Ghrelin mimetic | Published PK (Raun et al., 1998, PMID: 9849822) |
| GHRP-2 | ~15-25 minutes | SubQ / IV | Ghrelin mimetic | Published PK (Bowers et al., 1991) |
| GHRP-6 | ~15-20 minutes | SubQ / IV | Ghrelin mimetic | Published PK (Bowers, 1998) |
| MK-677 (Ibutamoren) | ~4-6 hours | Oral | GH secretagogue (non-peptide) | Published PK (Nass et al., 2008, PMID: 18981485) |
| Sermorelin | ~10-20 minutes | SubQ / IV | GHRH analog | Published PK (FDA label) |
| Hexarelin | ~60 minutes | SubQ / IV | Ghrelin mimetic | Published PK |
| Healing & Recovery Peptides | ||||
| BPC-157 | ~2 min (IV), est. 4-6 hr (subQ depot) | SubQ / Oral | Gastric pentadecapeptide | Animal PK data (estimated from detection windows) |
| TB-500 | Est. 2-4 hours | SubQ | Tβ4 fragment | Estimated (limited published PK) |
| GHK-Cu | Est. 30-60 minutes | SubQ / Topical | Copper tripeptide | Estimated (Pickart, 2008) |
| Thymosin Beta-4 (full) | Est. 1-2 hours | SubQ / IV | Actin-sequestering protein | Estimated from clinical studies |
| KPV | Est. 20-30 minutes | SubQ / Oral | α-MSH fragment | Estimated |
| Peptides | ||||
| Selank | ~30 sec – 3 min (native) / longer for analogs | Intranasal / SubQ | Tuftsin analog | Published PK (Zozulia et al., 2008) |
| Semax | ~30 sec – 3 min (native) | Intranasal | ACTH 4-7 analog | Published PK (Russian literature) |
| Dihexa | Est. 2-4 hours | SubQ / Oral (proposed) | HGF mimetic | Estimated from animal studies |
| DSIP | ~15-30 minutes | IV / SubQ | Nonapeptide | Published PK (Kafi et al., 1979) |
| Immune & Anti-Inflammatory | ||||
| Thymosin Alpha-1 (TA1) | <3 hours | SubQ | Thymic peptide | Published PK (Rost et al., 1999, PMID: 10027483) |
| LL-37 | Est. 30-60 minutes | SubQ / Topical | Cathelicidin | Estimated (susceptible to serum proteases) |
| Anti-Aging & Longevity | ||||
| Epitalon | Est. 2-3 hours | SubQ / IV | Tetrapeptide (Ala-Glu-Asp-Gly) | Estimated from Russian clinical studies (Khavinson) |
| MOTS-c | Est. 4-8 hours | SubQ | Mitochondrial-derived peptide | Estimated from animal PK data |
| NAD+ (IV infusion) | ~30-45 minutes (plasma) | IV | Coenzyme (not a peptide) | Published PK (limited human data) |
| Melanocortin Peptides | ||||
| Melanotan II | Est. 60 minutes | SubQ | MC1R/MC4R agonist | Estimated |
| PT-141 (Bremelanotide) | ~120 minutes (2 hours) | SubQ | MC3R/MC4R agonist | Published PK (FDA label, 2019) |
| Metabolic & Other | ||||
| AOD-9604 | Est. 30-60 minutes | SubQ / Oral | GH fragment (176-191) | Estimated from Phase 2 studies |
| Oxytocin | ~3-5 minutes (IV) | IV / Intranasal | Nonapeptide hormone | Published PK (FDA label) |
| Insulin (regular) | ~5-8 minutes (IV) | SubQ / IV | 51-aa hormone | Published PK (FDA label) |
Key: “Est.” = estimated from animal data, detection windows, or community-reported values. Not from published human PK studies. “Published PK” = data from peer-reviewed human pharmacokinetic studies or FDA/EMA drug labels.
The DAC difference: why CJC-1295 spans minutes to days
The most dramatic half-life difference in this table is CJC-1295 without DAC (~30 minutes) versus CJC-1295 with DAC (~8 days). Same peptide, 384x difference in half-life. How?
DAC (Drug Affinity Complex) is a reactive chemical group that covalently binds to serum albumin after injection. Once bound, the CJC-1295 molecule rides along with albumin — which has its own half-life of ~19 days in humans. The peptide effectively borrows albumin’s longevity.
Teichman et al. (2006) demonstrated that a single subcutaneous dose of CJC-1295 DAC produced sustained GH elevation for 6-8 days, with IGF-1 remaining elevated for 9-11 days (PMID: 16352683). Without DAC, the same peptide is cleared in under an hour.
This is the same principle (albumin binding) that gives semaglutide and tirzepatide their long half-lives — they use fatty acid acylation instead of covalent DAC bonding, but the mechanism is similar: hitch a ride on albumin to extend circulation time. For a deeper dive into how these molecular modifications work, see our GLP-1 pharmacokinetics guide.
GLP-1 agonist half-lives: why they dominate
The three GLP-1 agonists at the top of the table (semaglutide, tirzepatide, retatrutide) have half-lives measured in days while most peptides are measured in minutes to hours. This is entirely due to engineering.
Native GLP-1 has a half-life of ~2 minutes — it’s rapidly degraded by DPP-4 enzymes. The research compounds achieve 5-7 day half-lives through two modifications: DPP-4-resistant amino acid substitutions (preventing enzymatic degradation) and fatty acid acylation that promotes albumin binding (preventing renal clearance).
They reach steady state in 4-5 weeks. If you’re measuring acute pharmacological effects, you need to account for this long wash-in period.
Short-acting peptides: why minutes doesn’t mean ineffective
BPC-157’s ~2-minute IV half-life seems absurdly short. But half-life and efficacy aren’t the same thing. BPC-157’s reported effects have been linked to the NO system and to FAK-paxillin pathway activation (Sikiric et al., 2016, PMID: 27138887).
The peptide is the trigger, not the sustained effector.
Reconstituted solutions should be stored at 2-8°C and used within 28 days to maintain potency. Use our reconstitution calculator to work out concentrations, and check the peptide storage guide for detailed handling instructions.
How half-life affects storage stability
There’s a loose correlation between half-life and solution stability, but it’s not direct. Short half-life usually means the molecule is susceptible to enzymatic or chemical degradation — and those same vulnerabilities apply in the vial. Peptides with multiple basic residues (Arg, Lys) or free thiol groups (Cys) tend to degrade faster in solution.
General rules: lyophilized peptides at -20°C are stable for 6-24 months. Reconstituted peptides at 2-8°C last 21-28 days. Room temperature reconstituted peptides can lose significant activity within days. The shorter the half-life in vivo, the more critical proper storage becomes — because the same molecular vulnerabilities that cause rapid clearance also cause rapid degradation.
Frequently asked questions
What peptide has the longest half-life?
CJC-1295 with DAC at approximately 8 days, followed by semaglutide at ~7 days and cagrilintide at ~7 days. All three achieve long half-lives through albumin binding — DAC via covalent bonding, the others via fatty acid acylation. Without these modifications, native GLP-1 and native GHRH both have half-lives under 5 minutes.
What role does half-life play in experimental sampling design?
Half-life is one input into experimental sampling design but does not by itself determine it. BPC-157 (~2-minute half-life) is cleared rapidly; its reported effects are attributed to triggering downstream cascades rather than sustained receptor occupancy. The relationship between half-life and exposure depends on the mechanism of action.
Why is CJC-1295 DAC half-life so much longer than CJC-1295 without DAC?
The Drug Affinity Complex (DAC) covalently bonds to serum albumin after injection. Albumin has a ~19-day half-life in humans, so the peptide-albumin complex persists in circulation for days instead of minutes. Without DAC, CJC-1295 is a ~3 kDa peptide that’s rapidly cleared by the kidneys — below the ~60 kDa glomerular filtration threshold. With DAC, it becomes part of a ~70 kDa albumin complex that’s too large for renal clearance.
Limitations of this reference
- Many research peptides lack published human pharmacokinetic data. Values marked “Est.” are derived from animal studies or community reports and should be treated as approximations.
- Half-life varies by route of administration, individual metabolism, and co-administered compounds. Values shown are typical for the most common research route.
- This chart does not constitute dosing guidance. Research protocol design should reference primary literature for the specific compound and application.
References
- Lau J, et al. “Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.” J Med Chem. 2015;58(18):7370-7380. PMID: 26308095
- Teichman SL, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295.” JCEM. 2006;91(3):799-805. PMID: 16352683
- Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822
- Nass R, et al. “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults.” Ann Intern Med. 2008;149(9):601-611. PMID: 18981485
- Sikiric P, et al. “Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.” Curr Neuropharmacol. 2016;14(8):857-865. PMID: 27138887
- Dorr RT, et al. “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.” Life Sci. 1996;58(20):1777-1784. PMID: 8637402
All compounds discussed are for laboratory and educational research purposes only. Not for human consumption.
Patikrinkite prieš pradėdami tyrimą
Produktų puslapiuose rodoma klasės lygmens specifikacija, jei tokia yra užregistruota, o atrinktos partijos turi nepriklausomą trečiosios šalies COA.
